Great Point Partners increased its stake in Apogee Therapeutics (APGE) by 70,000 shares to 374,000 shares worth $28.23 million, making it the fund's largest holding at 9.15% of assets. APGE stock has doubled over the past year and is advancing monoclonal antibody therapies for inflammatory diseases with Phase 2 atopic dermatitis data expected in H1 2026.

Apogee Therapeutics reported positive interim Phase 1b results for zumilokibart (APG777), its anti-IL-13 antibody, in mild-to-moderate asthma patients, demonstrating rapid and durable suppression of FeNO biomarker through 16 weeks with a favorable safety profile. The company also highlighted multiple anticipated 2026 milestones including Phase 2 APEX data readouts in atopic dermatitis and potential Phase 3 initiation by late 2026, with a strong cash position of $913 million supporting operations into H2 2028.

Apogee Therapeutics reported positive Phase 1 trial results for APG333, a novel half-life extended TSLP antibody, demonstrating a 55-day half-life and potential for quarterly dosing in respiratory treatments.

Apogee Therapeutics successfully closed a public offering of 8,048,782 shares and pre-funded warrants, raising approximately $345 million to advance its clinical-stage biologics in inflammatory and immunology markets.

Apogee Therapeutics, a clinical-stage biotech company, announced a secondary stock offering of approximately 6.95 million shares at $41 per share, potentially raising around $300 million for preclinical studies, clinical trials, and research and development activities.

Apogee Therapeutics is conducting a public offering of 6,951,221 common stock shares and pre-funded warrants, expecting to raise approximately $300 million to support its clinical-stage biologics development.

Apogee Therapeutics reported positive 16-week data from its Phase 2 APEX clinical trial of APG777, an anti-IL-13 antibody for moderate-to-severe atopic dermatitis. The trial showed 71% reduction in EASI score and 66.9% of patients achieving EASI-75 response, with a favorable safety profile.

Apogee Therapeutics will report 16-week data from its Phase 2 APEX trial for APG777, a potential treatment for atopic dermatitis, on July 7, 2025, with a conference call and webcast to discuss the results.

Apogee Therapeutics announced positive interim results from a Phase 1b trial of its novel antibody APG808 in patients with mild-to-moderate asthma, showing rapid and sustained suppression of a biomarker of inflammation and a favorable safety profile.

Apogee Therapeutics announced progress in its Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule. The company also reported positive interim Phase 1 results for APG990, a novel half-life extended OX40L antibody, which exceeded trial objectives and demonstrated an approximately 60-day half-life.

Apogee Therapeutics announced positive interim Phase 1 results for its novel antibody APG990, which demonstrated a long half-life of around 60 days, supporting potential for infrequent dosing. The company plans to initiate a Phase 1b trial of the APG990 and APG777 combination (APG279) against DUPIXENT in 2025.

Apogee Therapeutics announced the first patient has been dosed in the Part B portion of the Phase 2 APEX clinical trial of APG777 for moderate-to-severe atopic dermatitis. The Part A portion of the trial exceeded enrollment targets, and the company plans to advance APG777 into additional indications.